Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Chiglitazar in Subjects with Renal Impairment
NCT05515458Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of chiglitazar in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum Plasma Concentration at 4 days, Area Under the Plasma Concentration-Time Curve from time zero to last measurable concentration at 4 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05515458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515458.